Advertisement
Screener

BIOGEN INC. (BIIB) Sales Revenue, Goods, Net (Deprecated 2018-01-31)

2.1 / 5 stars · 50/118 Roast Me

BIOGEN INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)

BIOGEN INC. (BIIB) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $2.52 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-24.

Discontinued › Expense Statement › Operating Expenses

us-gaap:SalesRevenueGoodsNet · last filed 2018-04-24

  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $2.52B, a 6.02% increase year-over-year.
  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $2.71B, a 8.37% increase year-over-year.
  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $2.62B, a 3.26% increase year-over-year.
  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $2.64B, a 7.04% increase year-over-year.
  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $10.35B, a 5.47% increase from fiscal 2016.
  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $9.82B, a 6.85% increase from fiscal 2015.
  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $9.19B, a 12.01% increase from fiscal 2014.
  • BIOGEN INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $8.20B, a 48.01% increase from fiscal 2013.
Period endSales Revenue, Goods, Net (Deprecated 2018-01-31) 3 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filedSales Revenue, Goods, Net (Deprecated 2018-01-31) 6 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filedSales Revenue, Goods, Net (Deprecated 2018-01-31) 9 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filedSales Revenue, Goods, Net (Deprecated 2018-01-31) 12 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed
2018-03-31$2.52B
10-Q · filed 2018-04-24
$5.24B
derived: sum of 2 quarters · filed 2018-04-24
$7.86B
derived: sum of 3 quarters · filed 2018-04-24
$10.50B
derived: sum of 4 quarters · filed 2018-04-24
2017-12-31$2.71B
10-K · filed 2018-02-01
$5.33B
derived: sum of 2 quarters · filed 2018-02-01
$7.97B
derived: sum of 3 quarters · filed 2018-02-01
$10.35B
10-K · filed 2018-02-01
2017-09-30$2.62B
10-K · filed 2018-02-01
$5.26B
derived: sum of 2 quarters · filed 2018-02-01
$7.64B
10-Q · filed 2017-10-24
$10.15B
derived: sum of 4 quarters · filed 2018-04-24
2017-06-30$2.64B
10-K · filed 2018-02-01
$5.02B
10-Q · filed 2017-07-25
$7.52B
derived: sum of 3 quarters · filed 2018-04-24
$10.06B
derived: sum of 4 quarters · filed 2018-04-24
2017-03-31$2.38B
10-Q · filed 2018-04-24
$4.88B
derived: sum of 2 quarters · filed 2018-04-24
$7.42B
derived: sum of 3 quarters · filed 2018-04-24
$9.89B
derived: sum of 4 quarters · filed 2018-04-24
2016-12-31$2.50B
10-K · filed 2018-02-01
$5.04B
derived: sum of 2 quarters · filed 2018-02-01
$7.51B
derived: sum of 3 quarters · filed 2018-02-01
$9.82B
10-K · filed 2018-02-01
2016-09-30$2.54B
10-K · filed 2018-02-01
$5.01B
derived: sum of 2 quarters · filed 2018-02-01
$7.32B
10-Q · filed 2017-10-24
$9.74B
derived: sum of 4 quarters · filed 2018-02-01
2016-06-30$2.47B
10-K · filed 2018-02-01
$4.78B
10-Q · filed 2017-07-25
$7.20B
derived: sum of 3 quarters · filed 2018-02-01
$9.59B
derived: sum of 4 quarters · filed 2018-02-01
2016-03-31$2.31B
10-K · filed 2018-02-01
$4.74B
derived: sum of 2 quarters · filed 2018-02-01
$7.13B
derived: sum of 3 quarters · filed 2018-02-01
$9.33B
derived: sum of 4 quarters · filed 2018-02-01
2015-12-31$2.43B
10-K · filed 2017-02-02
$4.82B
derived: sum of 2 quarters · filed 2017-02-02
$7.02B
derived: sum of 3 quarters · filed 2017-02-02
$9.19B
10-K · filed 2018-02-01
2015-09-30$2.39B
10-K · filed 2017-02-02
$2.39B
10-Q · filed 2015-10-21
$4.59B
derived: sum of 2 quarters · filed 2017-02-02
$6.76B
10-Q · filed 2016-10-26
$6.76B
10-Q · filed 2015-10-21
$9.05B
derived: sum of 4 quarters · filed 2017-02-02
2015-06-30$2.20B
10-K · filed 2017-02-02
$2.20B
10-Q · filed 2015-07-24
$4.37B
10-Q · filed 2016-07-21
$4.37B
10-Q · filed 2015-07-24
$6.66B
derived: sum of 3 quarters · filed 2017-02-02
$8.78B
derived: sum of 4 quarters · filed 2017-02-02
2015-03-31$2.17B
10-K · filed 2017-02-02
$2.17B
10-Q · filed 2015-04-24
$4.46B
derived: sum of 2 quarters · filed 2017-02-02
$6.58B
derived: sum of 3 quarters · filed 2017-02-02
$8.63B
derived: sum of 4 quarters · filed 2017-02-02
2014-12-31$2.29B
10-K · filed 2016-02-03
$4.40B
derived: sum of 2 quarters · filed 2016-02-03
$6.46B
derived: sum of 3 quarters · filed 2016-02-03
$8.20B
10-K · filed 2017-02-02
$8.20B
10-K · filed 2015-02-04
2014-09-30$2.12B
10-K · filed 2016-02-03
$2.12B
10-Q · filed 2014-10-22
$4.17B
derived: sum of 2 quarters · filed 2016-02-03
$5.92B
10-Q · filed 2015-10-21
$7.52B
derived: sum of 4 quarters · filed 2016-02-03
2014-06-30$2.06B
10-K · filed 2016-02-03
$2.06B
10-Q · filed 2014-07-23
$3.80B
10-Q · filed 2015-07-24
$5.41B
derived: sum of 3 quarters · filed 2016-02-03
$6.86B
derived: sum of 4 quarters · filed 2016-02-03
2014-03-31$1.74B
10-K · filed 2016-02-03
$1.74B
10-Q · filed 2014-04-23
$3.35B
derived: sum of 2 quarters · filed 2016-02-03
$4.80B
derived: sum of 3 quarters · filed 2016-02-03
$6.19B
derived: sum of 4 quarters · filed 2016-02-03
2013-12-31$1.61B
10-K · filed 2015-02-04
$3.06B
derived: sum of 2 quarters · filed 2015-02-04
$4.45B
derived: sum of 3 quarters · filed 2015-02-04
$5.54B
10-K · filed 2016-02-03
$5.54B
10-K · filed 2014-02-06
2013-09-30$1.45B
10-K · filed 2015-02-04
$1.45B
10-Q · filed 2013-10-28
$2.84B
derived: sum of 2 quarters · filed 2015-02-04
$3.94B
10-Q · filed 2014-10-22
$5.01B
derived: sum of 4 quarters · filed 2015-02-04
2013-06-30$1.39B
10-K · filed 2015-02-04
$1.39B
10-Q · filed 2013-07-25
$2.48B
10-Q · filed 2014-07-23
$3.56B
derived: sum of 3 quarters · filed 2015-02-04
$4.60B
derived: sum of 4 quarters · filed 2015-02-04
2013-03-31$1.10B
10-K · filed 2015-02-04
$1.10B
10-Q · filed 2013-04-25
$2.17B
derived: sum of 2 quarters · filed 2015-02-04
$3.21B
derived: sum of 3 quarters · filed 2015-02-04
$4.29B
derived: sum of 4 quarters · filed 2015-02-04
2012-12-31$1.07B
10-K · filed 2014-02-06
$2.11B
derived: sum of 2 quarters · filed 2014-02-06
$3.19B
derived: sum of 3 quarters · filed 2014-02-06
$4.17B
10-K · filed 2015-02-04
2012-09-30$1.04B
10-K · filed 2014-02-06
$1.04B
10-Q · filed 2012-10-25
$2.12B
derived: sum of 2 quarters · filed 2014-02-06
$3.09B
10-Q · filed 2013-10-28
$4.09B
derived: sum of 4 quarters · filed 2014-02-06
2012-06-30$1.08B
10-K · filed 2014-02-06
$2.05B
10-Q · filed 2013-07-25
$3.05B
derived: sum of 3 quarters · filed 2014-02-06
$4.02B
derived: sum of 4 quarters · filed 2014-02-06
2012-03-31$975.40M
10-K · filed 2014-02-06
$975.49M
10-Q · filed 2012-05-01
$1.97B
derived: sum of 2 quarters · filed 2014-02-06
$2.95B
derived: sum of 3 quarters · filed 2014-02-06
$3.90B
derived: sum of 4 quarters · filed 2014-02-06
2011-12-31$996.60M
10-K · filed 2013-02-05
$1.97B
derived: sum of 2 quarters · filed 2013-02-05
$2.93B
derived: sum of 3 quarters · filed 2013-02-05
$3.84B
10-K · filed 2014-02-06
2011-09-30$975.80M
10-K · filed 2013-02-05
$975.76M
10-Q · filed 2011-10-28
$1.93B
derived: sum of 2 quarters · filed 2013-02-05
$2.84B
10-Q · filed 2012-10-25
$3.75B
derived: sum of 4 quarters · filed 2013-02-05
2011-06-30$956.70M
10-K · filed 2013-02-05
$956.70M
10-Q · filed 2011-07-26
$1.86B
10-Q · filed 2012-07-24
$2.77B
derived: sum of 3 quarters · filed 2013-02-05
$3.65B
derived: sum of 4 quarters · filed 2013-02-05
2011-03-31$907.10M
10-K · filed 2013-02-05
$907.10M
10-Q · filed 2011-04-21
$1.82B
derived: sum of 2 quarters · filed 2013-02-05
$2.69B
derived: sum of 3 quarters · filed 2013-02-05
$3.55B
derived: sum of 4 quarters · filed 2013-02-05
2010-12-31$909.80M
10-K · filed 2012-02-03
$1.79B
derived: sum of 2 quarters · filed 2012-02-03
$2.65B
derived: sum of 3 quarters · filed 2012-02-03
$3.47B
10-K · filed 2013-02-05
2010-09-30$876.90M
10-K · filed 2012-02-03
$876.85M
10-Q · filed 2010-10-26
$1.74B
derived: sum of 2 quarters · filed 2012-02-03
$2.56B
10-Q · filed 2011-10-28
$3.39B
derived: sum of 4 quarters · filed 2012-02-03
2010-06-30$859.20M
10-K · filed 2012-02-03
$859.24M
10-Q · filed 2010-07-20
$1.68B
10-Q · filed 2011-07-26
$2.51B
derived: sum of 3 quarters · filed 2012-02-03
$3.31B
derived: sum of 4 quarters · filed 2012-02-03
2010-03-31$824.20M
10-K · filed 2012-02-03
$824.22M
10-Q · filed 2010-04-20
$1.65B
derived: sum of 2 quarters · filed 2012-02-03
$2.45B
derived: sum of 3 quarters · filed 2012-02-03
$3.24B
derived: sum of 4 quarters · filed 2012-02-03
2009-12-31$826.80M
10-K · filed 2011-02-04
$1.63B
derived: sum of 2 quarters · filed 2011-02-04
$2.42B
derived: sum of 3 quarters · filed 2011-02-04
$3.15B
10-K · filed 2012-02-03
2009-09-30$801.70M
10-K · filed 2011-02-04
$801.69M
10-Q · filed 2009-10-21
$1.59B
derived: sum of 2 quarters · filed 2011-02-04
$2.33B
10-Q · filed 2010-10-26
$3.06B
derived: sum of 4 quarters · filed 2011-02-04
2009-06-30$791.00M
10-K · filed 2011-02-04
$790.97M
10-Q · filed 2009-07-17
$1.52B
10-Q · filed 2010-07-20
$2.26B
derived: sum of 3 quarters · filed 2011-02-04
$3.01B
derived: sum of 4 quarters · filed 2011-02-04
2009-03-31$733.40M
10-K · filed 2011-02-04
$733.41M
10-Q · filed 2010-04-20
$1.47B
derived: sum of 2 quarters · filed 2011-02-04
$2.22B
derived: sum of 3 quarters · filed 2011-02-04
$2.91B
derived: sum of 4 quarters · filed 2011-02-04
2008-12-31$731.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04
$1.49B
derived: sum of 2 quarters · filed 2011-02-04
$2.17B
derived: sum of 3 quarters · filed 2011-02-04
$2.84B
10-K · filed 2011-02-04
2008-09-30$758.26M
10-Q · filed 2009-10-21
$1.44B
derived: sum of 2 quarters · filed 2009-10-21
$2.11B
10-Q · filed 2009-10-21
2008-06-30$684.49M
10-Q · filed 2009-07-17
$1.35B
10-Q · filed 2009-07-17
2007-12-31$2.14B
10-K · filed 2010-02-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29